Journal of Neuro-Oncology

, Volume 89, Issue 2, pp 211–218 | Cite as

Epithelial Growth Factor Receptor inhibitors for treatment of recurrent or progressive high grade glioma: an exploratory study

  • M. Preusser
  • E. Gelpi
  • A. Rottenfusser
  • K. Dieckmann
  • G. Widhalm
  • W. Dietrich
  • A. Bertalanffy
  • D. Prayer
  • J. A. Hainfellner
  • Christine Marosi
Clinical-patient studies


Introduction Erlotinib and Gefitinib (EGFRi) are small molecules specifically inhibiting epidermal growth factor receptor (EGFR). We present here data of an exploratory study evaluating EGFRi monotherapy in patients with recurrent or progressive malignant glioma. Patients 21 patients with recurrent or progressive malignant glioma were included in this study. EGFRi treatment was started at a median of 1.8 years (range 0.54 to 10.95) after initial surgery. 20/21 patients had undergone radiotherapy and all patients had received at least one (range 1 to 5, median 2) line of systemic antineoplastic therapy. Patients received 100 or 150 mg Erlotinib or 250 mg Gefitinib orally per day. Results Median age at primary diagnosis was 47.9 years (range 31.9 to 76 years). 18 patients received a total of 92.8 months (median 3.03) of Erlotinib treatment and 3 patients received a total of 16.1 months (median 6.06) of Gefitinib treatment. The best responses were partial remission in one patient receiving Erlotinib and in two patients receiving Gefitinib, respectively. Median time to progression was 3.05 months. Six months after start of EGFRi treatment, 4/21 (19%) patients were progression-free and 6/21(29%) patients were alive. Expression of EGFRwt, EGFRvIII, PTEN, phospho-Akt or EGFRvIII/PTEN co-expression in tumor cells did not significantly associate with time to progression or survival time. In one patient EGFRi administration had to be discontinued due to toxicity (grade 3 rash). Conclusion EGFRi monotherapy is associated with therapeutic efficacy in only a small fraction of patients with malignant gliomas. Biomarkers reliably predicting tumor response to EGFRi need to be identified.


Biomarker Epithelial Growth Factor Receptor Malignant glioma Prognosis Tyrosine-kinase inhibitor 



We thank Dr. Darell D. Bigner (Duke University, NC, USA) for providing L8A4 antibody and Gerda Ricken and Irene Leisser (both Institute of Neurology, Medical University of Vienna, Austria) for excellent technical assistance.


  1. 1.
    Stupp R, Hegi ME, van den Bent MJ et al (2006) Changing paradigms–an update on the multidisciplinary management of malignant glioma. Oncologist 11:165–180PubMedCrossRefGoogle Scholar
  2. 2.
    Louis N, Ohgaki H, Wiestler OD, Cavanee WK (eds) (2007) World Health Organization classification of tumours of the central nervous system. IARC Press, LyonGoogle Scholar
  3. 3.
    Ohgaki H, Kleihues P (2007) Genetic pathways to primary and secondary glioblastoma. Am J Pathol 170:1445–1453PubMedCrossRefGoogle Scholar
  4. 4.
    Aldape KD, Ballman K, Furth A et al (2004) Immunohistochemical detection of EGFRvIII in high malignancy grade astrocytomas and evaluation of prognostic significance. J Neuropathol Exp Neurol 63:700–707PubMedGoogle Scholar
  5. 5.
    Shinojima N, Tada K, Shiraishi S et al (2003) Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme. Cancer Res 63:6962–6970PubMedGoogle Scholar
  6. 6.
    Learn CA, Hartzell TL, Wikstrand CJ et al (2004) Resistance to tyrosine kinase inhibition by mutant epidermal growth factor receptor variant III contributes to the neoplastic phenotype of glioblastoma multiforme. Clin Cancer Res 10:3216–3224PubMedCrossRefGoogle Scholar
  7. 7.
    Haas-Kogan DA, Prados MD, Tihan T et al (2005) Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib. J Natl Cancer Inst 97:880–887PubMedGoogle Scholar
  8. 8.
    Kuan CT, Wikstrand CJ, Bigner DD (2001) EGF mutant receptor vIII as a molecular target in cancer therapy. Endocr Relat Cancer 8:83–96PubMedCrossRefGoogle Scholar
  9. 9.
    Normanno N, De Luca A, Bianco C et al (2006) Epidermal growth factor receptor (EGFR) signaling in cancer. Gene 366:2–16PubMedCrossRefGoogle Scholar
  10. 10.
    Bareschino MA, Schettino C, Troiani T et al (2007) Erlotinib in cancer treatment. Ann Oncol 18(Suppl 6):vi35–41PubMedCrossRefGoogle Scholar
  11. 11.
    Rocha-Lima CM, Soares HP, Raez LE et al (2007) EGFR targeting of solid tumors. Cancer Control 14:295–304PubMedGoogle Scholar
  12. 12.
    Prados MD, Lamborn KR, Chang S et al (2006) Phase 1 study of erlotinib HCl alone and combined with temozolomide in patients with stable or recurrent malignant glioma. Neuro Oncol 8:67–78PubMedCrossRefGoogle Scholar
  13. 13.
    Franceschi E, Cavallo G, Lonardi S et al (2007) Gefitinib in patients with progressive high-grade gliomas: a multicentre phase II study by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). Br J Cancer 96:1047–1051PubMedCrossRefGoogle Scholar
  14. 14.
    Halatsch ME, Schmidt U, Behnke-Mursch J et al (2006) Epidermal growth factor receptor inhibition for the treatment of glioblastoma multiforme and other malignant brain tumours. Cancer Treat Rev 32:74–89PubMedCrossRefGoogle Scholar
  15. 15.
    Raizer JJ (2005) HER1/EGFR tyrosine kinase inhibitors for the treatment of glioblastoma multiforme. J Neurooncol 74:77–86PubMedCrossRefGoogle Scholar
  16. 16.
    Rich JN, Reardon DA, Peery T et al (2004) Phase II trial of gefitinib in recurrent glioblastoma. J Clin Oncol 22:133–142PubMedCrossRefGoogle Scholar
  17. 17.
    Lassman AB, Rossi MR, Raizer JJ et al (2005) Molecular study of malignant gliomas treated with epidermal growth factor receptor inhibitors: tissue analysis from North American Brain Tumor Consortium Trials 01–03 and 00–01. Clin Cancer Res 11:7841–7850PubMedCrossRefGoogle Scholar
  18. 18.
    Mellinghoff IK, Wang MY, Vivanco I et al (2005) Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med 353:2012–2024PubMedCrossRefGoogle Scholar
  19. 19.
    Friedman HS, Bigner DD (2005) Glioblastoma multiforme and the epidermal growth factor receptor. N Engl J Med 353:1997–1999PubMedCrossRefGoogle Scholar
  20. 20.
    Macdonald DR, Cascino TL, Schold SC Jr. et al (1990) Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8:1277–1280PubMedGoogle Scholar
  21. 21.
    Choe G, Horvath S, Cloughesy TF et al (2003) Analysis of the phosphatidylinositol 3’-kinase signaling pathway in glioblastoma patients in vivo. Cancer Res 63:2742–2746PubMedGoogle Scholar
  22. 22.
    Perren A, Weng LP, Boag AH et al (1999) Immunohistochemical evidence of loss of PTEN expression in primary ductal adenocarcinomas of the breast. Am J Pathol 155:1253–1260PubMedGoogle Scholar
  23. 23.
    Van Den Bent MJ, Brandes AA, Rampling R et al: Randomized phase II trial of erlotinib versus temozolomide or BCNU in recurrent glioblastoma multiforme: EORTC 26034. American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, USAGoogle Scholar
  24. 24.
    Krishnan S, Brown PD, Ballman KV et al (2006) Phase I trial of erlotinib with radiation therapy in patients with glioblastoma multiforme: results of North Central Cancer Treatment Group protocol N0177. Int J Radiat Oncol Biol Phys 65:1192–1199PubMedGoogle Scholar
  25. 25.
    Agero AL, Dusza SW, Benvenuto-Andrade C et al (2006) Dermatologic side effects associated with the epidermal growth factor receptor inhibitors. J Am Acad Dermatol 55:657–670PubMedCrossRefGoogle Scholar
  26. 26.
    Wacker B, Nagrani T, Weinberg J et al (2007) Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies. Clin Cancer Res 13:3913–3921PubMedCrossRefGoogle Scholar
  27. 27.
    Li B, Chang CM, Yuan M et al (2003) Resistance to small molecule inhibitors of epidermal growth factor receptor in malignant gliomas. Cancer Res 63:7443–7450PubMedGoogle Scholar
  28. 28.
    Marie Y, Carpentier AF, Omuro AM et al (2005) EGFR tyrosine kinase domain mutations in human gliomas. Neurology 64:1444–1445PubMedGoogle Scholar
  29. 29.
    Cappuzzo F (2005) Erlotinib in gliomas: should selection be based on EGFR and Akt analyses? J Natl Cancer Inst 97:868–869PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC. 2008

Authors and Affiliations

  • M. Preusser
    • 1
  • E. Gelpi
    • 2
  • A. Rottenfusser
    • 3
  • K. Dieckmann
    • 3
  • G. Widhalm
    • 4
  • W. Dietrich
    • 4
  • A. Bertalanffy
    • 4
  • D. Prayer
    • 5
  • J. A. Hainfellner
    • 2
  • Christine Marosi
    • 1
  1. 1.Department of Internal Medicine 1Medical University of ViennaViennaAustria
  2. 2.Institute of NeurologyMedical University of ViennaViennaAustria
  3. 3.Department of Radiotherapy and RadiobiologyMedical University of ViennaViennaAustria
  4. 4.Department of NeurosurgeryMedical University of ViennaViennaAustria
  5. 5.Department of NeuroradiologyMedical University of ViennaViennaAustria

Personalised recommendations